Source: International Congress 2018 – Pathobiology of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Habbout (Québec, Canada), S. Provencher (Québec, Canada), S. Bonnet (Québec, Canada), O. Boucherat (Québec, Canada). Implication of the histone methyltransferase EZH2 in pulmonary arterial hypertension. 3925

Member's Comments

No comment yet.

Related content which might interest you: H3K27 histone lysine methylation as potential therapeutic target in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 Epigenome-wide mapping of histone modification landscape in human pulmonary arterial hypertension Source: ERS Lung Science Conference 2016 Year: 2016 LSC Abstract – Histone deacetylase 7 mediated metabolic remodeling: A new crosslink between pulmonary hypertension and cancer Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 LSC Abstract – Epigenome-wide mapping of histone modification landscape in human pulmonary arterial hypertension Source: International Congress 2016 – New genomic targets in pulmonary disease Year: 2016 Role and regulation of Jumonji C domain-containing histone demethylases 1A and 2B in pulmonary hypertension Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Prevention of fetal programming of pulmonary vascular dysfunction by a histone deacetylase inhibitor Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Decreased histone deacetylase activity in COPD Source: Annual Congress 2008 - Epigenetic modifications in lung disease Year: 2008 microRNA-223 suppresses histone deacetylase 2 in chronic obstructive pulmonary disease Source: International Congress 2015 – Latest news on miRNAs in pulmonary research Year: 2015 Role of class IIa histone deacetylases in the pathogenesis of pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Histone acetylation and deacetylation: importance in inflammatory lung diseases Source: Eur Respir J 2005; 25: 552-563 Year: 2005 Selective inhibition of BET bromodomain and their effect on nuclear factor-kappa B activation in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 Survivin inhibition as a potential target for pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Aberrant expression and activity of histone deacetylases in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench Year: 2013 HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Histone deacetylase activity and gene expression in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 316s Year: 2001 Citrullinated histone H3 is increased in blood of asthma subjects Source: International Congress 2019 – Understanding the mechanisms underlying airway diseases Year: 2019 Histone deacetylase activity is reduced in COPD. Modulation by theophylline Source: Eur Respir J 2003; 22: Suppl. 45, 4s Year: 2003 Functional upregulation of PRMT2 in chronic hypoxia-induced pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 721s Year: 2004 Steroids and histone deacetylase in ventilation-induced gene transcription Source: Eur Respir J 2007; 30: 865-877 Year: 2007